Cathie Wood Says If She Could Only Invest in 1 Artificial Intelligence (AI) Stock, This Would Be It (Hint: It's Not Palantir)

Cathie Wood's Ark Invest exchange-traded funds focus heavily on emerging technology themes such as artificial intelligence, cryptocurrencies, renewable energy, and data analytics.
While Ark has built major positions in numerous AI stocks, Wood revealed recently that Tesla is her highest-conviction holding.
In her view, Tesla is uniquely positioned to benefit from AI through autonomous vehicles and robotics -- markets that could be worth trillions of dollars.
These 10 stocks could mint the next wave of millionaires ›
Cathie Wood is the founder and chief investment officer of Ark Invest, which manages exchange-traded funds (ETFs) focused on themes such as biogenetics, artificial intelligence (AI), robotics, renewable energy, and cryptocurrencies.
While stocks such as Palantir Technologies, Robinhood, and Archer Aviation comprise some of the largest positions in Ark's portfolios, Wood recently revealed her highest-conviction pick. During an interview on The Diary of a CEO podcast, she said that if she could only invest in one stock, it would be Tesla (NASDAQ: TSLA), which is one of Ark's longest-standing positions and the top holding across all of its ETFs.
Let's dig into why Tesla has earned so much confidence from Wood. From there, I'll dig into how Tesla is disrupting several pockets of the AI realm and assess the company's valuation to help determine if the stock is a good buy right now.
During the interview, Wood described Tesla as a "convergence" across three arenas that Ark targets across its investments: robotics, energy storage, and AI.
For much of its history, Tesla focused on two core segments: electric vehicles and energy storage. While these two opportunities remain enormous, AI is the pillar supporting its growth narrative.
The first layer of Tesla's AI ambitions involves autonomous driving technology, which the company could market to both businesses and consumers. For example, self-driving functionality would be a big value-adding amenity for buyers of Teslas, which could help it maintain its differentiation in a crowded and commoditized automobile market.
The more lucrative opportunity when it comes to autonomous vehicles is connected to Tesla's plan to build a fleet of robotaxis. That could potentially send shock waves across markets from ride-hailing to car rentals to delivery services.
Wood is particularly bullish on Tesla's robotaxi project. During her interview, she clarified that Ark's $2,600 five-year price target on Tesla stock doesn't even account for the company's potential successes in other areas of AI that it's focusing on, such as robotics.
Beyond autonomous vehicles, Tesla is also investing heavily into a plan to create fleets of humanoid robots. This initiative, dubbed Optimus, has the potential to bring next-level efficiency to labor-heavy environments such as factory work or even in retail settings. Tesla CEO Elon Musk sees Optimus as tapping into a multitrillion-dollar opportunity.
One thing about Tesla is that the company never fails to find its way into headlines. Its stock price at any given time will be heavily dependent on the current narrative surrounding the company.
On the one hand, I personally view both the robotaxi and Optimus as exciting opportunities. Moreover, I am bullish about the potential of each of these businesses to transform Tesla from a carmaker and renewable energy business into more of a technology company.
With that said, however, I also understand that I need to be prudent when it comes to investing in businesses over storylines.
Tesla stock has been on a roll for a few months now. But its gains have had virtually nothing to do with the performance of the underlying business.
Instead, investors have been cheering on the stock for two peripheral reasons. First, Musk's departure from the Department of Government Efficiency (DOGE) gives him his time back to focus solely on Tesla and its various growth initiatives. Second, all signs are pointing toward a launch of Tesla's robotaxi service in its first market -- Austin, Texas -- this month.
The upward trajectory of Tesla stock right now isn't rooted in fundamentals. Rather, it is rooted in hype and excitement. It looks to me as if the good news of Musk's full-time return to Tesla and the robotaxi launch are priced into the stock already.
While I remain a Tesla bull for the long term, I would not buy into the momentum at these levels. Instead, I'd encourage investors to wait patiently and observe how the robotaxi service and Optimus begin contributing to Tesla's actual financial profile as those businesses launch and scale.
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $373,766!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $37,140!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $658,297!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 9, 2025
Adam Spatacco has positions in Palantir Technologies and Tesla. The Motley Fool has positions in and recommends Palantir Technologies and Tesla. The Motley Fool has a disclosure policy.
Cathie Wood Says If She Could Only Invest in 1 Artificial Intelligence (AI) Stock, This Would Be It (Hint: It's Not Palantir) was originally published by The Motley Fool

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

30 minutes ago

• Business Wire

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the following link: The event and accompanying slides can also be accessed by visiting the investor relations section of the company's website at An archived webcast will be available on the company's website following the event. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge (GC) induced symptoms. FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099). The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035). Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects. The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo. Gluten challenge induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain and abdominal bloating) reported during the 16 day gluten challenge from patient diaries/AE collection demonstrated a 42% benefit for FB102 treated subject (4.0 events per subject) compared to placebo (6.9 events per subject). There were no dropouts in the study. Treatment emergent adverse events (TEAE) were primarily mild (grade 1) with no grade 3 or higher SAEs reported in the FB102 arm. 'We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team. Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study. The Phase 2 celiac disease study is initiating with a topline readout expected in 2026.' said Paul Wagner, Ph.D. CEO and Chairperson of Forte Biosciences. 'These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes. We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026.' About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward-Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding Forte's beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102, the expected timeline for the Phase 2 celiac study and related readout, and the expected timing of topline results for the FB102 vitiligo study. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte's ability to obtain sufficient additional capital to continue to advance Forte's product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte's product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials; the risk that results from preclinical and the Phase 1b trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte's business and operating results is contained in Forte's Quarterly Report on Forms 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc.

The Verge

32 minutes ago

• The Verge

Tesla's robotaxi is live: here are some of the first reactions

Tesla finally did the damn thing. The company launched its hotly anticipated robotaxi service in Austin, Texas, on Sunday, June 22nd — and we're now starting to see some of the first reactions roll in. But first, we have to get a few important caveats out of the way. Tellingly, the service is not open to the general public, nor is it completely 'unsupervised,' as Elon Musk once promised. The vehicles will include Tesla-employed 'safety monitors' in the front passenger seat who can react to a dangerous situation by hitting a kill switch. Other autonomous vehicle operators would place safety monitors in the driver or passenger seats, but typically only during the testing phase. Tesla is unique in its use of safety monitors during commercial service. The rides are limited to a geofenced area of the city that has been thoroughly mapped by the company. And in some cases, Tesla is using chase cars and remote drivers as additional backup. (Some vehicles have been spotted without chase vehicles.) The service is invite only at launch, according to Tesla's website. A number of pro-Tesla influencers have received invites, which should raise questions about how unbiased these first critical reactions will be. Tesla hasn't said when the service will be available to the general public. The limited trial includes 10-20 Model Y vehicles with 'Robotaxi' branding on the side. The fully autonomous Cybercab that was first revealed last year won't be available until 2026 at the earliest. The service operates in a small, relatively safe area of Austin from 6AM to 12AM, avoiding bad weather, highways, airports, and complex intersections. Despite those hours, the robotaxi service seems to have gotten off to a slow start. Several invitees had yet to receive the robotaxi app by 1PM ET on Sunday. Sawyer Merritt, who posts pro-Tesla content on X, said he saw 30 Waymo vehicles go by while waiting for Tesla's robotaxi service to start. Musk posted at 1:12PM that the service would be available later that afternoon, adding that initial customers would pay a 'flat fee' of $4.20 for rides — a weed joke with which Musk has a troubled history. While riders waited, the company published a new robotaxi page to its website detailing a lot of the rules and guidelines of the service. Visitors are invited to sign up for updates about when Tesla's robotaxi service may come to their area. (Musk has said there could be up to a thousand robotaxis on the road 'in a few months.') After finally being granted access to the app, Merritt posted an image of the service area map, which appeared to cover a small area bordered by the Colorado River to the north, Highway 183 to the east, Highways 290 and 71 to the south, and Zilker Part to the west. And then the rides began — and they appeared to be mostly uneventful. Several invitees livestreamed themselves summoning their first cars, interacting with the UI, and then arriving at their destination. Several videos lasted hours, as the invitees would conclude a trip and then hail another car immediately after. One tester, Bearded Tesla Guy, described the app's interface as 'basically Uber.' Many had some difficulty finding the pickup location of their waiting Tesla robotaxi. 'This is like Pokemon hunting,' one person on Herbert Ong's livestream said, 'but its robotaxi hunting.' Once inside, the Tesla-employed safety monitor would ask the riders to show their robotaxi apps to prove their identities. Otherwise the safety monitors kept silent throughout the ride, despite riders trying to get them to talk. I'm assuming that Tesla will need to come up with some other way to identify their riders if they plan on removing the safety monitors from the passenger seat. Waymo, for example, asks customers to unlock their vehicle through the ridehail app. The rear screen instructs the riders to fasten their seatbelts, and after pressing an animated 'start ride' button, the vehicle gets underway. Riders can also start the ride from a similar button in the app. Since riders are registering for the robotaxi app using their preexisting Tesla profiles, they're greeted with their preferred music apps on the rear screen with all their playlists and saved tracks. The front display shows a visualization similar to consumer vehicles using Tesla's Full Self-Driving feature — even though Musk had said the robotaxis are running on a special version of FSD that's not available to the average Tesla owner. There are 'pull over,' 'stop in lane,' or 'support' buttons on the center display. Another tester, Chuck Cook, said the visualization lacked some of the controls that a normal Tesla might have. Pressing the support button places the rider in a queue as they wait for the remote operator to connect. On Cook's livestream, it took approximately two minutes before an operator finally connected. 'We appreciate you calling in,' the operator said (though the cellular connection was poor). 'We're here for any issues to support your ride.' Throughout the various trips, the robotaxis encountered a bevy of normal situations, like U-turns, speed bumps, pedestrians, construction, and more. The vehicles maintained speeds of about 40 mph or slower. Common words to describe the ride was 'smooth,' 'great,' and 'normal.' One tester said on X that they got the robotaxi to 'mess up' in a way that required the remote operator to help out — though they declined to describe it as a disengagement. Ashok Elluswamy, the head of the company's self-driving team, posted a photo of several dozen people in a room with 10 large monitors on the wall showing live camera feeds from several vehicles. 'Robotaxi launch party,' Elluswamy wrote. Where Tesla goes from here is the real challenge. Musk has said he also wants to launch a robotaxi service in California, where the regulatory process is a lot more complex than Texas. And even though he has said he wants to take things slow, he also claims that Tesla will have over a thousand driverless vehicles on the road 'within a few months.' Meanwhile, Waymo is operating more than 1,500 driverless vehicles in San Francisco, Los Angeles, Phoenix, and Austin — with plans to expand to Atlanta, Miami, and Washington, DC in the near future. The Alphabet-owned company has said it will grow its fleet to 2,000 vehicles by next year.

Yahoo

40 minutes ago

• Yahoo

Is Fox Stock Outperforming the Nasdaq?

New York-based Fox Corporation (FOX) operates as a news, sports, and entertainment company in the United States. With a market cap of $22.8 billion, the company operates through Cable Network Programming, Television, Credible, and The FOX Studio Lot segments. Companies worth $10 billion or more are generally described as "large-cap stocks." FOX fits right into that category, with its market cap exceeding the threshold, reflecting its substantial size and influence in the competitive industry of entertainment. FOX benefits from being one of the largest cable TV networks in the United States, offering a wide range of content. Robotaxis, Powell and Other Key Things to Watch this Week Make Over a 2.4% One-Month Yield Shorting Nvidia Out-of-the-Money Puts Is Quantum Computing (QUBT) Stock a Buy on This Bold Technological Breakthrough? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! FOX currently trades 7.8% below its all-time high of $55 recorded on Mar. 3. FOX's stock has gained 2.7% over the past three months, notably underperforming the Nasdaq Composite's ($NASX) 9.9% uptick during the same time frame. In the long term, FOX stock has surged 10.9% on a YTD basis, outperforming the Nasdaq's marginal increase. Moreover, shares of FOX soared 59% over the past 52 weeks, also outperforming Nasdaq's 9.7% returns over the same period. To confirm its bullish trend, FOX has been trading above its 200-day moving average for the past year and also above its 50-day moving average since mid-May. FOX shares rose 4.3% following the release of its better-than-expected Q3 earnings on May 12. The company's total revenues increased 26.8% year-over-year to $4.4 billion, mainly driven by a robust growth in the revenue of its affiliate fee, advertising, and other components, and also surpassed the Street's estimates. Its adjusted EBITDA, however, decreased 3.9% to $856 million, caused by an increase in expenses due to higher sports programming rights amortization and production costs driven by the broadcast of Super Bowl LIX and higher digital content and marketing costs. FOX's adjusted earnings increased marginally year-over-year to $1.09 and surpassed the consensus estimates by 14.6%. Its rival, News Corporation (NWSA), has gained 2.9% in 2025 and 5.4% over the past year, underperforming FOX. Among the 13 analysts covering the FOX stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $54.92 suggests an 8.2% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on